Trials / Terminated
TerminatedNCT00076401
A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)
Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (planned)
- Sponsor
- Pharmacyclics LLC. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have chronic lymphocytic leukemia (CLL) that has come back after treatment or that has stopped responding to treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Motexafin gadolinium |
Timeline
- First posted
- 2004-01-26
- Last updated
- 2014-06-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00076401. Inclusion in this directory is not an endorsement.